December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

93.74 +3.41 (+3.78%)
Streaming Delayed Price Updated: 3:01 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
News headline image
JPMorgan Elevates Incyte Price Target Amidst Robust Pipeline and Commercial Success, Yet Maintains Cautious "Neutral" Stance
JPMorgan Chase & Co. (NYSE: JPM) has recently recalibrated its outlook on the biopharmaceutical giant Incyte Corporation (NASDAQ: INCY), with a notable upward revision of its price target for the... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
What 14 Analyst Ratings Have To Say About Incyte ↗
 
Via Benzinga
News headline image
Which S&P500 stocks are gapping on Wednesday? ↗
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Wednesday to uncover the stocks that are gapping in the S&P500 index. 
Via Chartmill
News headline image
Incyte to Report Third Quarter Financial Results
From Incyte
Via Business Wire
News headline image
13 Analysts Have This To Say About Incyte ↗
 
Via Benzinga
News headline image
2 Reasons to Like INCY and 1 to Stay Skeptical
Incyte has had an impressive run over the past six months as its shares have beaten the S&P 500 by 19.6%. The stock now trades at $86.01, marking a 38% gain. This was partly due to its solid quarterly... 
Via StockStory
Topics Stocks
News headline image
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by... 
Via MarketMinute
News headline image
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
News headline image
STRATA Skin Sciences Soars as Landmark Study Reveals Superior Vitiligo Treatment Efficacy
STRATA Skin Sciences Inc. (NASDAQ: SSKN) witnessed a dramatic surge in its stock price today, climbing 51.18% following the publication of a groundbreaking peer-reviewed study. The research highlights... 
Via MarketMinute
Topics Intellectual Property
News headline image
Jim Cramer Spotlights These Undervalued S&P 500 Stocks With Growth Potential Amid Skyrocketing Market ↗
In a recent episode of "Mad Money," Jim Cramer identified several stocks in the S&P 500 that he believes are undervalued, offering growth potential despite the market's record highs. 
Via Benzinga
Topics Stocks
News headline image
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
From Incyte
Via Business Wire
News headline image
Incyte Stock: A Deep Dive Into Analyst Perspectives (11 Ratings) ↗
 
Via Benzinga
News headline image
FDA Expands Incyte's Opzelura Approval To Treat Atopic Dermatitis In Children ↗
FDA approves Incyte's Opzelura cream for children aged two and older with atopic dermatitis, expanding its use beyond teens and adults. 
Via Benzinga
News headline image
Incyte Corp (NASDAQ:INCY) Emerges as a Top Value Investing Candidate ↗
Incyte Corp (INCY) presents a strong value investing case with low P/E ratios, robust financial health, and high profitability in the biotech sector. 
Via Chartmill
News headline image
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
From Incyte
Via Business Wire
News headline image
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
From Incyte
Via Business Wire
News headline image
2 S&P 500 Stocks with Exciting Potential and 1 We Avoid
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
News headline image
3 Unpopular Stocks That Deserve a Second Chance
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
Via StockStory
News headline image
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
From Incyte
Via Business Wire
News headline image
Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
From Incyte
Via Business Wire
News headline image
Incyte (INCY) Stock Is Up, What You Need To Know
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 2.4% in the afternoon session after Barclays initiated coverage on the stock with an Overweight rating, helping the shares... 
Via StockStory
Topics Economy
News headline image
Tuesday's session: top gainers and losers in the S&P500 index ↗
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday. 
Via Chartmill
News headline image
1 Profitable Stock to Keep an Eye On and 2 We Question
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
News headline image
Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype? ↗
Analysts expect nearly 450% EPS growth in 2025, making execution on its core portfolio critical for sustaining the outperformance experienced so far YTD. 
Via MarketBeat
News headline image
Incyte Corp (NASDAQ:INCY): A Prime Candidate for Value Investors Seeking Undervalued Stocks ↗
Discover Incyte Corp (INCY), an undervalued biotech stock with strong profitability, solid financial health, and promising growth potential for value investors. 
Via Chartmill
News headline image
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
News headline image
S&P 500 Losers: 22 Stocks With Negative Returns Over Past 10 Years, And This One's Getting The Boot ↗
The S&P 500 Index is up over 200% over the past decade, but 22 stocks have declined during that period, and one is set to be removed soon. 
Via Benzinga
Topics Stocks
News headline image
Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
From Incyte
Via Business Wire
News headline image
1 Mid-Cap Stock with Solid Fundamentals and 2 We Find Risky
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.